All Peptide Calculators
Every page separates what is approved from what is not, and cites where its numbers came from. 8 approved drugs and 25 unapproved compounds.
How these pages decide what to publish
Every compound here sits on one of two tracks, and the track decides what appears on the page rather than how the page is worded. 8 of them have an FDA label. For those, the label’s own titration schedule is reproduced and cited — 3 carry a full escalation ladder with the interval between steps and the approved maximum.
The other 25 have no FDA label, and all but one have no approved human dose in any country (thymosin alpha-1 is approved abroad, for narrow uses). For those, no dosing schedule is published at all. What appears instead is the doses used in named studies, tagged with the species and the route they were given by, because an animal mg/kg figure is not a human dose and cannot be converted into one by arithmetic — the FDA’s own guidance on human equivalent dose exists precisely because that conversion is not a matter of body weight alone.
Where a figure has no source, the page says so instead of supplying one. 22 of the 33 compounds here have no published half-life we can cite, and each of those pages states that rather than quoting the number that circulates. That is the single largest difference between this site and the calculators it competes with, and it is deliberate: a gap reported honestly is more useful than a number with nothing behind it.
What the status badges mean
- FDA-approved — a marketed product exists with a prescribing label. The label governs, and the page quotes it.
- Category 1 — nominated for the 503A bulks list and under evaluation, with no significant safety risk identified so far. This is routinely presented by sellers as a form of approval. It is not approval, it is not inclusion on the list, and it does not create a dose.
- Category 2 — identified by the FDA as raising significant safety risks, which for peptides is typically immunogenicity from aggregation and peptide-related impurities.
- Removed from a list — frequently reported as promotion to a better category. It is not. A compound on no list has had nothing concluded about it, which is a weaker position than being on one.
GLP-1 and incretin
- TirzepatideFDA-approvedDual GIP and GLP-1 receptor agonist approved as Mounjaro (type 2 diabetes) and Zepbound (weight management and obstructive sleep apnea).
- SemaglutideFDA-approvedGLP-1 receptor agonist approved as Ozempic (type 2 diabetes), Wegovy (weight management, cardiovascular risk, MASH) and Rybelsus (oral).
- LiraglutideFDA-approvedOnce-daily GLP-1 receptor agonist approved as Victoza (type 2 diabetes) and Saxenda (weight management).
- RetatrutideInvestigational — not approved in any countryInvestigational triple GIP, GLP-1 and glucagon receptor agonist with positive phase 3 topline results. Not approved anywhere in the world.
- CagrilintideInvestigational — not approved in any countryInvestigational long-acting amylin analogue from Novo Nordisk, studied alone and in CagriSema with semaglutide. CagriSema is under FDA review; nothing containing cagrilintide is approved anywhere.
- SurvodutideInvestigational — not approved in any countryInvestigational glucagon and GLP-1 receptor dual agonist from Boehringer Ingelheim, licensed from Zealand Pharma, with published phase 3 obesity results. Not approved anywhere.
Repair and recovery
- BPC-157Not approved, and not lawfully compoundableA 15-amino-acid peptide studied almost entirely in rodents. No published human trial supports any of the injury-healing uses it is sold for, and no dose per kilogram of body weight exists for people.
- TB-500Not approved, and not lawfully compoundableA name that covers two different molecules. Real human trials exist for one of them — none used the injectable musculoskeletal route TB-500 is actually sold for.
- ARA-290Not approved; on the 503A list only in Category 3An eleven-amino-acid peptide engineered from erythropoietin that activates the innate repair receptor without stimulating red cell production. It reached phase 2 in sarcoidosis small-fibre neuropathy, then development stopped.
- BPC-157 + TB-500 blendNot approved; neither component is on any FDA listTwo research peptides premixed in one vial. Because they share a solution you cannot dose one without dosing the other, and the one study that tested the pair found no benefit from combining them.
- KLOW blendNot approved; no FDA recognition of the blendA vendor-defined four-peptide blend with no standard composition, no published research on the blend itself, and no dose anywhere in the literature.
- KPVNot approved anywhere; not on the 503A Bulks ListThe last three amino acids of alpha-MSH. Studied in mouse colitis models, mostly given orally; no human study of any kind exists.
Growth hormone axis
- CJC-1295Not approved; advisory committee voted against itSynthetic 29-amino-acid GHRH analogue. One published human study from 2006; the FDA's advisory committee voted against it in 2024 for lack of effectiveness evidence.
- IpamorelinNot approved; advisory committee voted against itSelective growth hormone secretagogue with exactly one published human study — a single-dose intravenous pharmacokinetic trial from 1999.
- IGF-1 LR3Not approved; never even nominatedA laboratory cell-culture reagent. No human trial has ever evaluated it for any endpoint, and its design makes hypoglycaemia the dose-limiting risk.
- CJC-1295 + Ipamorelin blendNot approved; advisory committee voted against both componentsA GHRH analogue and a growth hormone secretagogue premixed in one vial. The FDA's advisory committee voted against both, separately.
- Tesamorelin + Ipamorelin blendThe blend is not approved and is not EGRIFTAAn unapproved fixed-ratio blend that should not be confused with FDA-approved tesamorelin products. No study has tested the combination.
- TesamorelinFDA-approvedA GHRH analogue approved for HIV-associated lipodystrophy, and one of the few approved peptides that genuinely ships as a powder you reconstitute yourself.
- SermorelinApproval withdrawn in 2009; no current FDA productOnce FDA-approved as Geref, withdrawn in 2009. No label survives on FDA's systems, which means no reconstitution volume for it has a primary source.
- HGH (somatropin)FDA-approvedRecombinant human growth hormone. The one peptide on this site with an official milligram-to-IU conversion — 3 IU per mg.
Metabolic
- MOTS-cNot approved, and not lawfully compoundableA 16-amino-acid mitochondrial-derived peptide. Every efficacy dose ever published for MOTS-c itself was given to a mouse by intraperitoneal injection; no human dose has been published.
- AOD-9604Not approved; advisory committee voted against itA growth hormone fragment whose large human obesity trial was actually run — and failed its primary endpoint. Development stopped in 2007.
- NAD+Category 1 under evaluation; no approved injectable productA dietary ingredient by mouth and an unapproved drug when injected. Small human infusion studies establish tolerability at a slow rate and nothing about efficacy.
- SS-31 (elamipretide)FDA-approved for Barth syndrome only (accelerated approval)Approved in September 2025 as FORZINITY, for muscle strength in Barth syndrome only — supplied as a ready-made solution, not a powder.
Other
- DSIPNot FDA-approved; FDA review weighed against 503A listingEmideltide, a nine-amino-acid peptide studied decades ago by intravenous infusion. Small insomnia trials were inconsistent, and no human subcutaneous dose has been studied.
- VesugenNot approved; never evaluated by the FDAA synthetic tripeptide from the Khavinson “peptide bioregulator” programme. The weakest evidence base of anything on this site.
- Kisspeptin-10Not approved anywhere, and in FDA 503A Category 2A ten-amino-acid fragment of kisspeptin studied in humans almost entirely as an intravenous infusion in physiology experiments lasting hours. It is in FDA 503A Category 2, and it is prohibited in sport at all times.
- Thymosin Alpha-1Not FDA-approved; approved abroad as ZADAXINA 28-amino-acid thymic peptide. Not FDA-approved, but approved abroad as ZADAXIN — for chronic hepatitis B in Indonesia and as an add-on to flu vaccination in Italy.
- HCGFDA-approved (intramuscular use only)Chorionic gonadotropin, dosed in USP units rather than milligrams. Approved, reconstituted, and with a discard window that differs by brand.
- PT-141FDA-approved as a solution, not as a powderApproved as Vyleesi for hypoactive sexual desire disorder — as a ready-to-use autoinjector, not as a powder.
- EpitalonNot approved anywhere; not on the 503A Bulks ListA synthetic four-amino-acid peptide, not the same thing as the pineal extract epithalamin. Almost all of its data comes from one research group, and its only human trial measured a melatonin metabolite.
Skin and cosmetic
- GHK-CuCategory 1 for non-injectable routes onlyCopper tripeptide with genuinely good evidence applied topically — and no human data at all for the injectable use it is sold for.
- GLOW peptide blendNot approved; GLOW is a vendor-defined blendA vendor-defined GHK-Cu, BPC-157 and TB-500 blend with no standard formula, no clinical trial of the combination and no published human dose.
How the framework above is sourced
The regulatory framework these pages apply comes from the documents below. Each individual calculator carries its own sources for its own numbers.
- RegulatorFDABulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
- RegulatorFDA· 2026-05-14Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
- RegulatorFDACertain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
- RegulatorFDACompounding Risk Alerts
- RegulatorWorld Anti-Doping Agency· 2026WADA 2026 Prohibited List
- RegulatorFDA / CDER· 2005-07Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers — Guidance for Industry (Table 1, body surface area conversion factors)